Previous Article | Next Article 
Journal of Virology, September 1998, p. 7040-7047, Vol. 72, No. 9
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
CD4+ Cytotoxic T-Lymphocyte Activity
against Macrophages Pulsed with Bovine Herpesvirus 1 Polypeptides
Chong
Wang and
Gary A.
Splitter*
Department of Animal Health and Biomedical
Science, University of Wisconsin
Madison, Madison, Wisconsin 53706
Received 30 March 1998/Accepted 20 May 1998
 |
ABSTRACT |
Bovine herpesvirus 1 (BHV-1) induces immune suppression, but the
mechanisms for suppression are not well identified. We examined the
induction and activity of BHV-1-specific cytolytic CD4+ T
lymphocytes (CTL) by stimulating peripheral blood mononuclear cells
(PBMC) of cattle immunized with attenuated live BHV-1. Cytolytic effector cells were primarily CD4+ T lymphocytes and lysed
autologous, but not allogeneic, macrophages infected with BHV-1 or
pulsed with BHV-1 polypeptides. Apoptosis of BHV-1-expressing target
cells was observed in CD4+ CTL assays by terminal
deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL)
analysis. To determine if apoptosis was mediated by a perforin- or
Fas-mediated pathway, EGTA, a known selective inhibitor of the perforin
pathway, was used. EGTA did not inhibit
CD4+-T-cell-mediated cytotoxic activity, but it did limit
the NK cell cytotoxicity of virus infected cells. These findings
support the concept that CD4+ CTL lyse macrophages pulsed
with BHV-1 polypeptides through a Fas-mediated lytic pathway by
inducing apoptosis in the target cells. The prominent cytotoxicity
mediated by CD4+ CTL suggests a mechanism of selective
removal of viral antigen-associated antigen-presenting cells.
 |
INTRODUCTION |
Bovine herpesvirus 1 (BHV-1) is a
member of the Alphaherpesvirinae subfamily. Other members of
the subfamily include herpes simplex virus (HSV), pseudorabies virus,
and equine herpesvirus. Like these viruses, BHV-1 afflicts both the
respiratory and genital tracts (15). Because herpesvirus
persists in the presence of specific antiviral antibody and because a
cell-to-cell viral transfer pathway of infection occurs
(39), cell-mediated immunity is considered an important
mechanism in viral elimination (5, 9). This idea is
supported by cytotoxic T-lymphocyte (CTL) activity against viral
surface glycoproteins gB, gC, and gD in HSV-1 and BHV-1 infection
(14) and by protection from lethal HSV-1 challenge in mice
by adoptive transfer of immune T cells (30).
Interestingly, BHV-1, as well as HSV, is known to down-regulate the
expression of major histocompatibility complex (MHC) class I molecules
(25, 32). Inhibition of MHC class I expression on the
surface of infected cells would probably interfere with the protective
function of CD8+ CTL. Although bovine CD8+ CTL
have been reported as a mechanism to lyse BHV-1-infected cells
(14), these CTL cells are difficult to demonstrate in vitro
(37). Mechanisms other than CD8+ CTL may play an
important role in controlling viral infection.
In HSV infection, CD4+ CTL activity has been proposed as
one of the major immune mechanisms to control HSV recurrence in
herpesvirus stromal keratitis in humans (10), and mice
(16). In fact, early efforts to clone CTL specific for HSV-1
and HSV-2 resulted in CD4+ rather than CD8+ CTL
clones (46, 47). In HSV infection, both CD4+ and
CD8+ HSV-specific CTL were induced with UV-inactivated HSV
or live HSV stimulation (35, 40). In contrast to HSV, little
is known about the protective mechanisms against BHV-1.
CTL trigger target cell death though T-cell receptor-peptide-MHC
complex involvement. CD8+ CTL can lyse target cells through
either Fas- or perforin-mediated cell death (27). The
Fas-dependent pathway may play a more prominent role in
CD4+-, rather than, CD8+-CTL-mediated lysis.
CD4+ T cells may even lyse exclusively through the
Fas-mediated lytic pathway (24, 27). However,
perforin-mediated cytotoxicity by human CD4+ CTL has been
found in a CD4+-T-cell clone and in peripheral
CD4+ T cells (43, 45), although perforin
expression is confined mainly to CD8+ T cells, natural
killer (NK) cells, and 
T cells. Recently, bovine Fas cDNA was
isolated and its nucleotide sequence was determined (48),
providing support for the notion that this Fas lytic mechanism may
exist in cattle. The identification of bovine Fas provides support for
the notion that CD4+ CTL may lyse target cells through the
Fas-mediated lytic pathway in cattle (48). In humans,
CD4+ CTL lyse antigen-pulsed target macrophages by inducing
apoptosis (11).
Our work focused on the possible mechanisms of bovine CD4+
CTL lysis of cells expressing BHV-1 peptides. Defining the mechanism(s) of cellular protection in BHV-1 infection is a critical step to understanding viral pathogenesis and controlling viral spread. The
present study characterizes the phenotype and functional aspects of CTL
detectable in peripheral blood mononuclear cells (PBMC) of
BHV-1-immunized cattle, using autologous macrophages pulsed with BHV-1
polypeptides or infected with live BHV-1. The CTL could serve as a
major immune mechanism against BHV-1 infection, as well as a possible
role in selective elimination of virus-infected antigen-presenting
cells.
 |
MATERIALS AND METHODS |
Animals, cells, and virus strains.
Normal healthy cattle
(Jersey, Holstein, or Guernsey), 2 to 8 years old, were housed at the
University of Wisconsin
Madison Dairy Cattle Center and were used for
all experiments. Cattle were immunized annually with a strain of
temperature-sensitive modified live bovine
rhinotracheitis-parainfluenza 3 vaccine (SmithKline Beecham,
Philadelphia, Pa.) and were seropositive for BHV-1. Blood was taken for
experiments throughout the year irrespective of the date of
immunization. Culture supernatant containing BHV-1 (Cooper strain ATCC
VR-864) was harvested after infection of MDBK cells (ATCC CCL 22) for 3 days. The MDBK cells were cultured in RPMI 1640 containing 10%
heat-inactivated fetal bovine serum (FBS), 100 U of penicillin per ml,
and 100 µg of gentamicin per ml. The BHV-1 infectivity titer was
determined by limiting-dilution titer determination in MDBK cells.
BHV-1 (McIntyre) was kindly provided by Judd Aiken (University of
Wisconsin
Madison). Bovine leukemia virus (BLV) was recovered from the
BL3 cell line (ATCC CRL 8037) by ultracentrifugation at 140,000 × g for 2.5 h. Autologous adherent macrophages and the
canine osteosarcoma cell line D17 (ATCC CCL183) were used as target
cells.
Peptide preparation.
BHV-1 virions from culture supernatant
were precipitated by ultracentrifugation at 140,000 × g for 2.5 h. The virus pellet was dissolved in 70%
formic acid, and 500 mg of cyanogen bromide (Sigma Chemical Co., St.
Louis, Mo.) was added to the virus suspension overnight at room
temperature (31). The solvent was evaporated under a stream
of nitrogen overnight, and the residue was suspended in water. The
nitrogen-treated BHV-1 residue was purified twice on a Sephadex G-75
column, and the fractions containing polypeptides were collected and
lyophilized. The BHV-1 polypeptides were assessed by sodium dodecyl
sulfate (SDS)-gel electrophoresis, and no intact BHV-1 remained in the
cyanogen bromide-treated BHV-1 preparations. Ovalbumin (OVA) (grade VI;
Sigma), BLV, and HSV-1 were prepared similarly to BHV-1 to obtain
polypeptides.
Antibodies and immunofluorescent staining.
Monoclonal
antibodies 16-1E10 (anti-CD2), and biotin-labeled C5B6 (anti-CD11c)
were produced in our laboratories (18, 19). Additional
monoclonal antibodies were SBU-T8 (anti-CD8; University of Melbourne,
Parkville, Victoria, Australia), CC15 (specific for the WC1 molecule on
bovine 
T cells; Chris Howard, Institute for Animal Health,
Compton, England), IL-A12 (anti-CD4; C. Baldwin) (3), 33 (anti-immunoglobulin M [IgM]; Klaus Nielsen, Animal Research
Institute, Nepean, Ontario, Canada), P1.17 (an isotype control, ATCC
TIB10), W6/32 (anti-MHC class I; Accurate Chemical & Scientific Corp,
Westbury, N.Y.), and H4 (anti-MHC class II; One Lambda, Los Angeles,
Calif.). One-color immunofluorescence was performed with
fluorescein-conjugated goat anti-mouse IgG (heavy plus light chains)
(Jackson ImmunoResearch Laboratories, Inc., Avondale, Pa.). Monoclonal
antibody CAM36A (anti-CD14) (Veterinary Medical Research and
Development, Pullman, Wash.) was biotin labeled as specified by the
instructions accompanying the EZ-Link NHS-LC-biotinylation kit (Pierce,
Rockford, Ill.). The percentage of fluorescent cells was determined by
flow cytometry (EPICS; Coulter, Hialeah, Fla.).
Activation of virus-specific cytotoxic cells.
PBMC were
recovered from the interface following centrifugation (25°C for 30 min at 1,800 × g) of venous blood through
Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). After being washed three
times in 1× phosphate-buffered saline (PBS), recovered cells were
resuspended in RPMI 1640 (Sigma) supplemented with 2 mM
L-glutamine, 25 mM HEPES, 5 × 10
5 M
2-mercaptoethanol, 100 U of penicillin per ml, 100 µg of streptomycin per ml, and 10% FBS (Equitech-Bio, Ingram, Tex.). Isolated PBMC were
cultured in RPMI 1640 in 25-cm2 tissue culture flasks
(2 × 107 cells/flask) with UV-inactivated BHV-1 at a
multiplicity of infection (MOI) of 2 and 50 U of recombinant human
interleukin-2 (rhIL-2; Boehringer Mannheim). Virus inactivation
following UV irradiation was confirmed by a lack of viral replication
in MDBK cells. BHV-1-exposed cytotoxic effector cells were generated
after 7 to 10 days of culture at 37°C under 5% CO2.
CTL assay.
In CD4+-CTL assays, the PBMC cultured
with UV-inactivated BHV-1 were used as effector cells while the
adherent macrophages pulsed with BHV-1 polypeptides were used as target
cells. Briefly, macrophages isolated from PBMC were cultured in
six-well cell culture plates as target cells in RPMI 1640-10% FBS
after 1 week at 37°C in a humidified 5% CO2 incubator.
Each well of six-well plates contained 5 × 105 to
10 × 105 adherent macrophages, and BHV-1 polypeptides
or live BHV-1 (MOI, 10) was added 2 or 12 h before the CTL assays.
The target cells were labeled with 250 µCi of 51Cr for
1 h, trypsinized, washed three times with 1× PBS, and incubated with the effector cells in triplicate at 5 × 103
cells in round-bottom microtiter wells at 37°C for 6 h. Effector cells were washed twice and added in triplicate to the plated target
cells at various effector-to-target ratios. The total volume was 200 µl/well. The assay mixture was incubated for 4 h in a humidified
5% CO2 incubator at 37°C, and following culture, 100 µl of supernatant/well was counted in a gamma counter. Samples were
counted as positive when the mean exceeded the control by 3 standard
deviations in 51Cr release. Data were used only if the
spontaneous release was less than 25% of the maximum release. The
percent specific 51Cr release was calculated from the
following formula: percent specific lysis = 100 × (cpm
experimental
cpm spontaneous lysis)/(cpm total release
cpm spontaneous lysis). NK-like cytotoxicity was determined with
freshly isolated PBMC as effector cells and D17 cells infected with
BHV-1 at an MOI of 10 for 2 h as target cells. NK-like assay
mixtures were incubated for 18 h at 37°C under 5% CO2. The chemical inhibitors EGTA, MgCl2, or
CaCl2 were added at the beginning of selected CTL or
NK-like assays.
DNA apoptosis analysis.
Standard CTL assays were performed,
except that the target cells were not labeled with
Na51CrO4. After 4 h of incubation, medium
control and experimental cells were transferred into 1.8-ml tubes. All
cells were incubated with biotinylated anti-CD11c and anti-CD14
antibodies for 30 min at 4°C. After being washed with 1× PBS, the
cells were treated with phycoerythrin-conjugated streptavidin (1:100)
(Jackson ImmunoResearch Laboratories) for 30 min at 4°C. After two
washes with 1× PBS, all the cells were treated as specified by the
protocol of the In Situ Cell Death kit (Fluorescein) (Boehringer
Mannheim, Indianapolis, Ind.). The cells were fixed with 4%
paraformaldehyde. After two washes with 1× PBS, the cells were
permeabilized (0.1% Triton X-100 in 0.1% sodium citrate) for 2 min on
ice. Adherent macrophages were collected and washed twice with 1× PBS.
The macrophages serving as a positive control were treated with 10 U of
RQ-DNase (Promega, Madison, Wis.) for 10 min at room temperature.
Following two washes with 1× PBS, the cells (including positive
control macrophages) were incubated with the TUNEL (terminal
deoxynucleotidyltransferase-mediated dUTP nick end labeling) reaction
mixture (terminal deoxynucleotidyltransferase, fluorescein-labeled
nucleotide mixture). The macrophages serving as a negative control were
incubated with the fluorescein-labeled nucleotide mixture without
terminal transferase. Target cells were analyzed by flow cytometry and
gated by a combination of forward and 90° light scatter.
Depletion of CD4+ and CD8+ T-lymphocyte
subsets.
Effector cells (2 × 107 cells) were
depleted of CD4+ or CD8+ T lymphocytes after 7 to 8 days in culture by using anti-CD4 (IL-12A) or anti-CD8 (SBU-T8)
antibodies, washed twice, and treated with 1:5 rabbit complement
(Cedarlane Laboratories, Hornby, Ontario, Canada) on ice for 30 min.
The effector cells were washed twice before being reconstituted in RPMI
1640 with 10% FBS, and an aliquot of treated effector cells was
analyzed by flow cytometry for cell phenotype.
CD4+-T-lymphocyte enrichment.
In the effector
cell population, CD8+ T cells, 
+ T cells,
and B cells were selectively depleted by using anti-CD8 (SBU-T8), anti-WC1 (CC15), and anti-IgM (33) antibodies with an AIS
MicroCELLector (Applied Immune Sciences, Inc., Menlo Park, Calif.) as
recommended by the manufacturer. By using this selection technique,
CD4+ T cells were enriched to greater than 95% as
confirmed by flow cytometry.
MHC class II typing.
Lymphocytes were typed for BoLA-D
by restriction fragment length polymorphism (12, 36).
Briefly, chromosomal DNA from donor PBMC was isolated with the
TurboGen-Genomic DNA purification kit (Invitrogen, San Diego, Calif.).
Genomic DNA (20 µg) was digested with PvuII and
TaqI (Promega), and the digests were electrophoresed in 1%
Tris-borate-EDTA (TBE)-agarose gels followed by capillary transfer to
Magna NT nylon transfer membranes (MSI, Westboro, Mass.). The membranes
were prehybridized and hybridized with formamide hybridization
solutions at 42°C (50% formamide, 1% SDS, 10% dextran sulfate, 200 µg of salmon sperm DNA per ml) for 4 h and overnight, respectively. Human HLA-DR
, HLA-DR
, HLA-DQ
, and HLA-DQ
cDNAs (ATCC 57392, ATCC 57080, ATCC 57390, and ATCC 57082, respectively) were used as hybridization probes. The cDNAs were
isolated from their plasmids and 32P-labeled by the
random-primer method (Life Technologies Inc., Gaithersburg, Md.).
Following hybridization, the membranes were washed in 0.4 M NaOH at
45°C for 30 min and subsequently twice in 0.2× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% SDS-0.2 M Tris (pH 7.5) at
room temperature for 10 min to remove the probes. Then the transfer
membranes were washed twice in 2× SSC-0.5% SDS for 10 min and once
in 1.0× SSC-0.5% SDS at 60°C for 40 min. The membranes were
exposed to autoradiographic film at
70°C for 1 to 5 days.
 |
RESULTS |
CTL effector cell phenotype.
We have previously shown that T
lymphocytes from BHV-1-immunized donors proliferated in response to
recombinant herpesvirus proteins (28). To determine the
phenotype of responding cells, PBMC cultured with UV-inactivated BHV-1
for 7 to 10 days were incubated with MAbs and analyzed by flow
cytometry. After 7 days of culture, CD4+ T lymphocytes
increased as the dominant cell subpopulation, ranging from 70 to 90%,
in contrast to the situation for PBMC cultured without BHV-1 (Table
1). The percentage of CD8+ T
cells as well as that of 
+ T cells remained
relatively unchanged following culture of the cells with virus for 7 days. Typically, 2.5 × 107 to 3.7 × 107 viable cells/flask were recovered following culture.
The increase in the number of CD4+ T lymphocytes suggests
that these cells are BHV-1 responsive. To determine the function of
these cultured cells, we tested BHV-1-specific T-lymphocyte activity.
BHV-1-specific CTL and antigen dose-dependent CTL activity.
In
the murine system, exogenous peptides can be presented through both
exogenous and endogenous pathways and can be expressed with MHC class I
and II molecules on the cell surface (6, 31). Because
macrophages are infected with BHV-1 (21), we used autologous macrophages infected with BHV-1 or pulsed with BHV-1 polypeptides as
target cells for BHV-1-specific CTL. The results of a CTL assay representative of 12 assays are shown in Fig.
1A. By this criterion, BHV-1 seronegative
cattle were uniformly negative. CTL assays were carried out on cells
stimulated with UV-inactivated BHV-1 in vitro for 7 to 10 days in the
presence or absence of exogenous rhIL-2. It is unlikely that the
observed BHV-1-specific cytolysis is an artifact of prolonged culture
or exogenous cytokines, since cytokines alone were unable to induce
detectable antigen-specific CTL activity (Fig. 1A). rhIL-2 at 80 U per
ml improved the consistency of cytolysis among different CTL assays.
However, increased rhIL-2 concentrations greater than 100 U/ml in the
effector cell culture lead to nonspecific effector cell lysis of both
nonpulsed and antigen-pulsed target cells (data not shown). Since
macrophages pulsed with BHV-1 polypeptides served as target cells,
antigen concentrations were titrated to determine the minimal antigen quantity for optimal CTL activity (Fig. 1B). At an
effector-to-target-cell ratio of 50:1, BHV-1-specific lysis increased
as the BHV-1 polypeptide concentration increased to 200 µg/ml.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 1.
(A) BHV-1-specific CTL were induced in PBMC bulk
cultures stimulated with UV-inactivated BHV-1 (MOI, 10). The effector
cells were PBMC isolated from BHV-1 immunized cattle and stimulated
with UV-inactivated BHV-1 and rhIL-2 at 80 U/ml for 7 to 10 days.
Target cells were macrophages recovered from PBMC and pulsed for 2 h with BHV-1 polypeptides and 1 h with 51Cr before the
CTL assays. The CTL assay mixtures were incubated for 6 h.
Effector cells from a nonimmunized seronegative animal served as a
control. This result is representative of 12 separate experiments. (B)
BHV-1 polypeptide antigen (Ag) concentration was titrated for CTL
activity. At an effector-to-target (E:T) ratio of 50:1, BHV-1-specific
lysis increased as the BHV-1 polypeptide concentration increased.
Samples were counted as positive when the mean lysis exceeded the
medium control by 3 standard deviations. The spontaneous release was
less than 25% of the maximum release. This experiment was repeated
once with similar results.
|
|
Freshly isolated PBMC or unstimulated, cultured lymphocytes from
BHV-immunized or nonimmunized donors did not show appreciable lysis of
autologous targets (Fig. 1A). Different target antigens were used to
determine the viral specificity of CTL (Fig.
2). Antigen-specific CTL activity
confirmed that macrophages pulsed with BHV polypeptides were lysed by
BHV-1-stimulated PBMC while autologous macrophages pulsed with
polypeptides of OVA, BLV, or the related HSV-1 were not lysed by
BHV-stimulated PBMC, similar to the medium control (Fig. 2). The
success of finding BHV-specific CD4+ CTL was confirmed
repeatedly in BHV-1-immunized cattle of Holstein, Jersey, and Guernsey
breeds (data not shown).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
The antigen specificity of bovine CTL was determined by
using different target antigens in CTL assays. BHV-1, OVA, BLV, and
HSV-1 were treated with cyanogen bromide (CNBr) to produce
polypeptides. Autologous macrophages were lysed by effector cells only
when BHV-1 polypeptides were added. Similar results were obtained in
three additional experiments. Symbols: , CNBr plus BHV-1; , live
BHV-1; , CNBr plus HSV; , CNBr plus OVA; , CNBr plus BLV;
, no antigen.
|
|
The CTL response is mediated by CD4+ cells.
To
identify the phenotype of the effector cell population, subpopulations
of cultured PBMC were negatively selected by specific antibodies plus
complement. CD4+, CD8+, and 
+
T lymphocytes were selectively removed from cultured PBMC before CTL
assays by using anti-CD4, anti-CD8, anti-
, and isotype control monoclonal antibodies plus rabbit complement. Flow cytometry confirmed that greater than 95% CD4+, CD8+, and

+ T lymphocytes were depleted by using the respective
antibodies (data not shown). Effector cells treated with the IgG2a
isotype control monoclonal antibody (P1.17) plus rabbit complement
showed a similar cell phenotype to nontreated effector cells. Following antibody and complement treatment, effector cells were used in CTL
assays (Fig. 3). CD4+-T-cell
depletion led to a marked loss of CTL activity against autologous
macrophages pulsed with BHV-1 polypeptide. In contrast, neither
CD8+ T-cell nor 
+ T-cell depletion
correlated with the loss of BHV-1-specific cytolysis. Thus,
CD4+-T-cell depletion with the resulting absence of
BHV-1-specific cytolysis strongly suggested that BHV-1-specific CTLs
are CD4+ T lymphocytes which were generated from PBMC
stimulated in vitro with UV-inactivated BHV-1 (Fig. 3).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
The BHV-1-specific CTL response is mediated by
CD4+ T cells. Individual cell populations of BHV-1-infected
cultured PBMC were negatively selected by specific antibodies plus
complement. The CD2+- or CD4+-T cell deletion
led to the absence of BHV-1-specific cytolysis. cont., control; C',
complement.
|
|
To further confirm the importance of BHV-1-specific
CD4+-T-cell cytolysis, individual effector cell
subpopulations were enriched. Isolated CD4+ T cells were
approximately 95% of the cell population after negative selection by a
panning technique (data not shown). CTL assays performed with these
enriched CD4+ T cells lysed macrophages pulsed with BHV-1
polypeptides (Fig. 4). Similar attempts
were made to enrich CD8+ T lymphocytes and

+ T lymphocytes; however, insufficient
CD8+ and 
+ T cells were obtained for CTL
assays. Positive CD4+-T-cell selection was not performed
since unrestricted cytolytic effector cells are produced by
cross-linking CD4 molecules during positive selection (7).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 4.
Enriched CD4+ T lymphocytes mediated the
lysis of BHV-1 polypeptide-pulsed target cells. The enriched
CD4+ CTL activity paralleled the nonenriched effector cell
population. Symbols: , PBMC effector cells; , enriched
CD4+ T cells; , medium control.
|
|
CD4+ CTLs are MHC restricted.
To determine the
role of MHC in peptide recognition by CD4+ CTL, BoLA class
II alleles were characterized by restriction fragment length
polymorphism (RFLP) (2, 36). Each of the animals possessed unrelated class II HLA-DQ
alleles (data not shown) based on RFLPs reported for the nine classes of class II genes found in cattle (1, 12). Additional RFLP studies further elucidated that the
animals possessed unrelated BoLA class II HLA-DR
and HLA-DR
(data
not shown). Thus, the cattle were MHC class II unrelated in DR and DQ
alleles. After BoLA typing, autologous and allogeneic CTL assays were
performed to evaluate CD4+ CTL MHC restriction. As
expected, BHV-stimulated lymphocytes exhibited virus-specific lysis
against only autologous targets and no lysis against mismatched
allogeneic macrophages presenting viral peptides (Fig.
5). These data indicate that the
BHV-1-specific immune response can be mediated by CD4+, MHC
class II-restricted T cells in attenuated BHV-1-vaccinated cattle.
Inhibition of BHV-1-specific cytolysis was attempted by using anti-MHC
class I (W6/32), anti-MHC class II (H4), anti-CD4 (IL-A12), or anti-CD8
(SBU-T8) antibodies added to effector cells 30 min before the CTL
assays. Minimal inhibition of CTL activity was observed in any
monoclonal antibody combination in assays repeated two or three times
(data not shown).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 5.
BHV-1-specific CD4+ CTL are MHC restricted.
BHV-1 stimulated CTL from immunized cattle exhibited no virus-specific
lysis activity against mismatched allogeneic macrophages pulsed with
BHV polypeptides. Antigen-specific CD4+ CTL lysed only
autologous macrophages pulsed with BHV-1 polypeptides. This result is
representative of six separate experiments.
|
|
CD4+-CTL-mediated cellular cytotoxicity is not blocked
by Mg2+ and EGTA.
To evaluate the perforin or Fas
pathway involvement in CD4+ CTL lysis of macrophages pulsed
with BHV-1 polypeptides, EGTA and MgCl2 were added to the
CTL assay mixture as a Ca2+ chelator to remove free
Ca2+ in the medium at the beginning of the assays. In the
presence of 4 mM EGTA, antigen-specific CD4+-CTL activity
was not inhibited, suggesting that CD4+ CTL activity is not
sensitive to the absence of free Ca2+ in the medium of the
assays (Fig. 6). Since the
perforin-mediated lytic pathway is sensitive to the absence of calcium
while the Fas-mediated lytic pathway is not (27), these
results suggested that CD4+ CTL may involve the
Fas-mediated lytic pathway.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 6.
CD4+ CTL are not Ca2+ dependent
and may use the Fas-mediated lytic pathway. Addition of selected
concentrations of Mg2+ and EGTA (Ca2+ chelator)
to the CD4+ CTL assay mixtures did not inhibit BHV-specific
cytolytic activity, suggesting that antigen-specific CD4+
CTL are not calcium dependent. Medium was added to macrophage target
cells as a negative control for miscellaneous lytic activity in CTL
assays. Similar results were obtained in five separate experiments.
|
|
NK-like cytotoxicity is blocked by Mg2+ and EGTA.
NK-cell cytotoxicity assays were performed as a control for
CD4+-CTL activity since NK cells in general lyse their
target cells through a perforin-mediated lytic pathway (9,
27). D17 cells infected with BHV-1 served as target cells and
noncultured PBMC served as effector cells in an 18-h cytotoxicity
assay. NK-cell cytolytic activities were inhibited by 1.5 mM EGTA plus
MgCl2 and could be partially recovered by calcium addition
(data not shown). This finding suggests that NK-cell cytotoxicity
requires free calcium for lytic function and parallels the requirements of the lytic pathway.
Apoptosis of target cells is mediated by CD4+ CTL.
The macrophage target cells were gated for size and complexity by flow
cytometry and analyzed for fluorescence by the TUNEL method.
Approximately 30% of target cell macrophages pulsed with BHV-1
polypeptides exhibited programmed cell death after the 4-h CTL assay
compared to 7% of macrophages in the medium control (Fig.
7).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 7.
Apoptosis of macrophages pulsed with viral polypeptides
induced by CD4+ CTL. All macrophages were treated with
anti-macrophage antibodies (anti-CD11c and anti-CD14) and were gated by
forward and low-angle light scatter as large and complex cells. The
anti-CD11c and anti-CD14 antibodies were labeled with phycoerythrin
(red fluorescence) to identify macrophages, while the fragmented DNA of
apoptotic cells were labeled with fluorescein isothiocyanate-dUTP by
terminal deoxynucleotidyltransferase (green fluorescence). Intact
macrophages were either not labeled with fluorescein
isothiocyanate-dUTP (negative control) (A) or not labeled with
fluorescein isothiocyanate-dUTP (positive control) (B). Compared to the
target cells without viral polypeptide treatment (medium control) (C),
about 30% of target cells pulsed with BHV-1 polypeptides exhibited
apoptosis in CTL assays (D).
|
|
Cells were treated with biotin-labeled anti-CD11c and anti-CD14
antibodies, specific for leukocyte function antigen-1 and the
lipopolysaccharide receptors, respectively, present on macrophages and
were then treated with phycoerythrin-conjugated streptavidin. Then the
large, complex cells were gated as candidates for apoptosis evaluation.
In viral polypeptide-specific CTL assays, 30% of target cells were
positive by TUNEL analysis, compared to about 7% of target cells not
treated with viral peptides, suggesting that CD4+ CTL lysed
autologous macrophages through an apoptotic pathway. Parallel
51Cr cytotoxicity assays indicated that CD4+
CTL lysed 40% of autologous macrophages pulsed with BHV-1 polypeptides (Fig. 8).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 8.
A standard 51 Cr CTL assay was performed in
parallel with the TUNEL CTL assay in Fig. 7, demonstrating
CD4+ CTL lysis of autologous macrophages pulsed with BHV-1
polypeptides. The "medium" curve indicates macrophages cultured
without viral polypeptides. Antigen-specific lysis of the
51Cr-releasing CTL assay (indicated by the "BHV-1
polypeptides" curve) was within the same range as the apoptosis
observed in Fig. 3D.
|
|
 |
DISCUSSION |
Our data indicated that BHV-specific CD4+ CTL
precursors are present in peripheral blood of BHV-seropositive cattle,
the natural host for this infection. BHV-1-specific cytolytic activity
of CD4+ T cells can be induced after PBMC are cocultured
with UV-inactivated virus. This observation supports the hypothesis
that CD4+ CTL are preferentially activated by cell-free
UV-inactivated BHV while CD8+ CTL are stimulated primarily
by fixed BHV-infected fibroblasts (15). Such a differential
activation has also been reported for cell-free HSV activating
CD4+ T cells, whereas HSV-infected fibroblasts primarily
stimulated CD8+ T cells (44).
Our findings indicate the effector cells produced in response to
cell-free BHV-1 could lyse autologous macrophages pulsed with BHV-1
polypeptides. The cytolytic activities are BHV-1-antigen specific,
since macrophages pulsed with OVA, BLV, and related HSV polypeptides or
macrophages without antigen could not be lysed by similar effector
cells. Similarly, live BHV-1-infected macrophages can serve as target
cells lysed by CD4+ CTL. However, results obtained with
pulsed BHV polypeptides were more consistent than those obtained with
live virus for several possible reasons. First, the inconsistency
observed with live virus could result from variation in
macrophage-virus infection (21) or virus induced macrophage
death. Second, live virus may induce apoptosis of CD4+ T
cells, as observed in bovine CD4 T cells with BHV-1 infection (20) and in human CD4 T cells from cord blood with human
immunodeficiency virus type 1 infection (26). Third,
peptide-bound class II MHC molecule complexes are more heterogeneous
than those produced by intracellular processing, indicating that
peptide-pulsed macrophages may be recognized by a more diverse group of
CTL than are virus-infected macrophages (42).
However, in BHV-1 infection, the role of CTL, important cells in many
viral infections, has received minimal attention (37). BHV-1
infection in murine and bovine fibroblasts down-regulates MHC class I
expression (25, 32), as well as class I transcription. Interfering with MHC class I expression, BHV could escape a
CD8+ CTL immune response. Similar herpesviruses, e.g., HSV,
Epstein-Barr virus, and cytomegalovirus, have confirmed mechanisms to
evade the immune system by blocking viral antigen loading by
transporters associated with antigen processing to MHC class I
molecules (22, 29). Studies with BHV-1 have identified that
modified live vaccines, as well as wild-type virus, can decrease MHC
class I but not class II expression (32). The virus mediates
this effect by interfering with the synthesis of class I heavy chain
and the assembly/transport of class I molecules by 8 to 12 h.
Although blocking viral antigen transfer to the endoplasmic reticulum
has not been confirmed in BHV-1 infection, this unique herpesvirus
evasive mechanism supports the importance of cytolytic CD4+
lymphocytes in herpesvirus infection. Therefore, activation of CD4+ CTL during BHV infection could compensate for the loss
of BHV-1-specific CD8+ CTL activity caused by viral
down-regulation of MHC class I antigen presentation.
Macrophages expressing MHC class II molecules are infected by BHV-1,
and expression of MHC class II can be enhanced by a variety of stimuli,
particularly gamma interferon (IFN-
) and tumor necrosis factor
alpha. Also, after IFN-
treatment, class II molecules can be induced
in other cell types, e.g., vascular endothelial cells, dermal
fibroblasts, placental cells, and melanocytes (23). Activated T lymphocytes can express MHC class II molecules, and BHV-1
infection can induce local leukocyte infiltration and IFN-
production by activated T lymphocytes (39). Therefore, cells other than macrophages and B cells might express MHC class II molecules
and viral peptides during BHV-1 infection. In bovine Theileria
parva infection, culture of infected 
+ T cells,

+ T cells, and B-cell lines revealed high expression
of MHC class II molecules. However, in vivo, MHC class II-negative
parasitized lymphocytes progressively outnumbered MHC class II-positive
parasitized cells, suggesting that host-mediated destruction or
antigenic modulation of parasitized MHC class II-expressing cells was
occurring (13). Similarly, BHV-1-specific CD4+
CTL may play an important role to control BHV-1 infection in vivo by
killing virus infected cells transiently expressing MHC class II
molecules.
The often massive infiltration of leukocytes in herpesvirus infection
could result in extensive cytokine production. In herpetic stromal
keratitis, human epidermal keratinocytes are induced to express HLA
class II (DR) molecules by IFN-
and HSV-infected are killed by both
CD4+ T lymphocytes and NK cells (10, 16). Thus,
depletion of certain antigen-presenting cells by CD4+ T
cells could regulate the immune response in herpesvirus infection, potentially polarizing or influencing cytokine production without severe immunopathology (4).
In contrast, depletion of MHC class II-bearing macrophages by
CD4+ CTL could also limit the local immune response to
BHV-1 infection, suppressing immune surveillance and allowing the virus
to escape. Macrophages play an important role in controlling virus
spread during the initial stage of virus infection. The monocytes and macrophages obtained from BHV-1-infected animals produce IFN-
, function as cytotoxic cells, and express increased MHC class II molecules, serving as antigen-presenting cells for further activation of virus-specific immune response (39). Presumably, these
activities are directed to limit virus spread; therefore, depletion of
macrophages from infected animals could subvert immune functions that
control viral infection. In this context, CD4+-CTL activity
may be a major immune system mechanism for removal of virus-infected
cells and control of virus spread, or it could be an immunosuppressive
mechanism where CD4+ CTL help the virus evade immune
responses. Further studies and direct evidence are needed to clarify
the possibility of antigen-specific CD4+ CTL facilitating
virus spread.
Interestingly, our parallel studies of apoptosis by using TUNEL
analysis and standard 51Cr release CTL assays revealed
comparable levels of cell death, an observation similar to others
(8) supporting a mechanism of programmed cell death
initiated by CD4+ CTL. CD4+ CTL are believed to
predominantly use the Fas-mediated lytic pathway (17),
although occasionally they use the perforin-mediated lytic pathway
(27, 38, 45). Macrophages can express Fas (CD95) molecules
on the cell surface, and there is evidence that Th1-type
CD4+ CTL lyse target cells through Fas-mediated apoptosis
(11, 33, 34). Perforin undergoes a calcium-induced
conformational change, forming pores on the target cell membrane that
are inhibited in the absence of free Ca2+ by the
Ca2+ chelator Mg2+ and EGTA, while
Fas-dependent cytotoxicity is only minimally inhibited in the presence
of EGTA (27). In our CTL assays, cytotoxicity is not
inhibited by EGTA, suggesting that CD4+ CTL lyse
BHV-1-polypeptide-pulsed macrophages through the Fas-mediated lytic
pathway. In contrast, NK-cell cytolytic activity, used for comparison,
involves the perforin-mediated lytic pathway (41). The
NK-cell cytotoxicity was inhibited in the absence of Ca2+,
and addition of Ca2+ to the cytotoxicity assay mixtures
restored the NK-cell cytotoxicity. The present studies suggest that NK
cells may lyse BHV-1-infected target cells through the
perforin-dependent pathway while CD4+ CTL mediate lysis
through the Fas-dependent pathway. In contrast to the present
observations, others have observed that HSV-1 could induce the
apoptosis of CD4 T cells but apoptosis was not inhibited by anti-Fas or
anti-FasL antibodies (26). These workers concluded that
Fas-FasL was not the mechanism of apoptosis. However, virus-altered cells may use the same intracellular apoptotic pathway but not require
surface Fas-FasL triggering for apoptosis induction. Additional studies
to explore the role of the Fas-dependent pathway could utilize caspase
inhibitors to block CTL activity, measuring caspase activity in target
cells following effector cell treatment, or inhibiting Fas-FasL
interaction by monoclonal antibody treatment. Presently, anti-bovine
Fas or FasL antibodies are not available.
Our experiments revealed the presence of CD4+ CTL
precursors in animals immunized by attenuated BHV-1 vaccine. The
successful induction of CD4+ CTL from bovine peripheral
blood showed the long-anticipated scenario of CD4+ CTL
involvement in cell-mediated immunity against BHV-1 infection. CD4+ CTL may induce the apoptosis of macrophages through
Fas-mediated lysis, suggesting BHV-1-specific CD4+ CTL
probably compensate for the loss of CD8+ CTL since BHV-1
can down-regulate MHC class I expression in infected cells (25,
32). However, since CD4+ CTL also lysed
virus-infected antigen-presenting cells, we predict that
CD4+ CTL might actually limit a local immune response;
therefore, in vivo, CD4+ CTL may control viral spread and
limit the local immune response to viral infection.
 |
ACKNOWLEDGMENTS |
This work is supported by grants USDA 93-37204-9205 and
96-35204-3670.
We thank Yi Gao, Linda Eskra, and Jerome Harms for providing critical
reagents and for many helpful discussions.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Animal Health and Biomedical Sciences, 1655 Linden Dr., Madison, WI
53706. Phone: (608) 262-1837. Fax: (608) 262-1837. E-mail:
splitter{at}ahabs.wisc.edu.
 |
REFERENCES |
| 1.
|
Andersson, L., and C. J. Davies.
1994.
The major histocompatibility complex, p. 37-57.
In
B. M. L. Goddeeris, and W. I. Morrison (ed.), Cell-mediated immunity in ruminants. CRC Press, Inc., Boca Raton, Fla.
|
| 2.
|
Andersson, L. B. J.,
L. Rask, and P. A. Anderson.
1986.
Genomic hybridization of bovine class II major histocompatibility genes. 1. Extensive polymorphism of DQ and DQ genes.
Anim. Genet.
17:95-112[Medline].
|
| 3.
|
Baldwin, C. L.,
A. J. Teale,
J. G. Naessens,
B. M. Goddeeris,
N. D. MacHugh, and W. I. Morrison.
1986.
Characterization of a subset of bovine T lymphocytes that express BoT4 by monoclonal antibodies and function: similarity to lymphocytes defined by human T4 and murine L3T4.
J. Immunol.
136:4385-4391[Abstract].
|
| 4.
|
Braakman, E.,
F. T. M. Rotteveel,
G. V. Bleek,
G. A. V. Seventer, and C. J. Lucas.
1987.
Are MHC class II-restricted cytotoxic T lymphocytes important?
Immunol. Today
8:265-267.
|
| 5.
|
Campos, M.,
P. Griebel,
H. Bielefeldt Ohmann, and L. A. Babiuk.
1992.
Cell-mediated cytotoxic responses in lungs following a primary bovine herpes virus type 1 infection.
Immunology
75:47-52[Medline].
|
| 6.
|
Carbone, F. R.,
M. W. Moore,
J. M. Sheil, and M. J. Bevan.
1988.
Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptide.
J. Exp. Med.
167:1767-1779[Abstract/Free Full Text].
|
| 7.
|
Choi, S. H., and G. A. Splitter.
1994.
Induction of MHC-unrestricted cytolytic CD4+ T cells against virus infected target cells by cross-linking CD4 molecules.
J. Immunol.
153:3874-3881[Abstract].
|
| 8.
|
Cohen, J. J.
1993.
Apoptosis.
Immunol. Today
14:126-130[Medline].
|
| 9.
|
Cook, C. G.,
G. J. Letchworth, and G. A. Splitter.
1989.
Bovine naturally cytolytic cell activation against bovine herpes virus type 1-infected cells does not require late viral glycoproteins.
Immunology
66:565-569[Medline].
|
| 10.
|
Cunningham, A. L., and J. R. Noble.
1989.
Role of keratinocytes in human recurrent herpetic lesions. Ability to present herpes simplex virus antigen and act as target for T lymphocyte cytotoxicity in vitro.
J. Clin. Invest.
83:490-496.
|
| 11.
|
Dalit, A.,
X. Song,
E. Lacy,
J. Nikolic-Zugic,
S. M. Friedman, and K. B. Elkon.
1995.
Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway.
Proc. Natl. Acad. Sci. USA
92:11223-11229.
|
| 12.
|
Davies, C. J.,
L. Andersson,
I. Joosten,
P. Mariani,
L. C. Gasbarre, and E. J. Hensen.
1992.
Characterization of bovine MHC class II polymorphism using three typing methods: serology, RFLP, and IEF.
Eur. J. Immunogenet.
19:253-262[Medline].
|
| 13.
|
DeMartini, J. C.,
N. D. MacHugh,
J. Naessens, and A. J. Teale.
1993.
Differential in vitro and in vivo expression of MHC class II antigens in bovine lymphocytes infected by Theileria parva.
Vet. Immunol. Immunopathol.
35:253-273[Medline].
|
| 14.
|
Denis, M.,
M. Slaoui,
G. Keil,
L. A. Babiuk,
E. Ernst,
P.-P. Pastoret, and E. Thiry.
1993.
Identification of different target glycoproteins for bovine herpes virus type 1-specific cytotoxic T lymphocytes depending on the method of in vitro stimulation.
Immunology
78:7-13[Medline].
|
| 15.
|
Denis, M.,
G. Splitter,
E. Thiry,
P.-P. Pastoret, and L. A. Babiuk.
1994.
Infectious bovine rhinotracheitis (bovine herpesvirus 1): helper T cells, cytotoxic T cells, and NK cells, p. 157-172.
In
B. M. L. Goddeeris, and W. I. Morrison (ed.), Cell-mediated immunity in ruminants. CRC Press, Inc., Boca Raton, Fla.
|
| 16.
|
Doymaz, M. Z.,
C. M. Foster,
D. Destephano, and B. T. Rouse.
1991.
MHC II-restricted, CD4+ cytotoxic T lymphocytes specific for herpes simplex virus-1: implications for the development of herpetic stromal keratitis in mice.
Clin. Immunol. Immunopathol.
61:398-409[Medline].
|
| 17.
|
El-Khatib, M.,
B. Z. Stanger,
H. Dogan,
H. Cui, and S.-T. Ju.
1995.
The molecular mechanism of FasL-mediated cytotoxicity by CD4+ Th1 clones.
Cell. Immunol.
163:237-244[Medline].
|
| 18.
|
Eskra, L.,
K. L. O'Reilly, and G. A. Splitter.
1991.
Effect of monoclonal antibodies on in vitro function of T-cell subsets.
Vet. Immunol. Immunopathol.
27:215-222[Medline].
|
| 19.
|
Eskra, L.,
K. L. O'Reilly, and G. A. Splitter.
1991.
The bovine p150/95 molecule (CD11c/CD18) functions in primary cell-cell interaction.
Vet. Immunol. Immunopathol.
29:213-227[Medline].
|
| 20.
|
Eskra, L., and G. A. Splitter.
1997.
Bovine herpesvirus-1 infects activated CD4+ lymphocytes.
J. Gen. Virol.
78:2159-2166[Abstract].
|
| 21.
|
Forman, A. J., and L. A. Babiuk.
1982.
Effect of infectious bovine rhinotracheitis virus infection on bovine alveolar macrophage function.
Infect. Immun.
35:1041-1047[Abstract/Free Full Text].
|
| 22.
|
Fruh, K.,
K. Ahn,
H. Djaballah,
P. Sempe,
P. M. van Endert,
R. Tampe,
P. A. Peterson, and Y. Yang.
1995.
A viral inhibitor of peptide transporters for antigen presentation.
Nature
375:415-418[Medline].
|
| 23.
|
Glimcher, L. H., and C. J. Kara.
1992.
Sequences and factors: a guide to MHC class-II transcription.
Annu. Rev. Immunol.
10:13-49[Medline].
|
| 24.
|
Hahn, S.,
R. Gehri, and P. Erb.
1995.
Mechanism and biological significance of CD4-mediated cytotoxicity.
Immunol. Rev.
146:57-79[Medline].
|
| 25.
|
Hariharan, M. J.,
C. Nataraj, and S. Srikumaran.
1993.
Down regulation of murine MHC class I expression by bovine herpesvirus 1.
Viral Immunol.
6:273-284[Medline].
|
| 26.
|
Ito, M.,
W. Koide,
M. Watanabe,
H. Kamiya, and M. Sakurai.
1997.
Apoptosis of cord blood T lymphocytes by herpes simplex virus type 1.
J. Gen. Virol.
78:1971-1975[Abstract].
|
| 27.
|
Kagi, D.,
B. Ledermann,
K. Burki,
R. M. Zinkernagel, and H. Hengartner.
1996.
Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo.
Annu. Rev. Immunol.
14:207-232[Medline].
|
| 28.
|
Leary, T. P., and G. A. Splitter.
1990.
Recombinant herpesviral proteins produced by cell-free translation provide a novel approach for the mapping of T lymphocyte epitopes.
J. Immunol.
145:718-723[Abstract].
|
| 29.
|
Levitskaya, J.,
M. Coram,
V. Levitsky,
S. Imreh,
P. M. Steigerwald-Mullen,
G. Klein,
M. G. Kurilla, and M. G. Masucci.
1995.
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
Nature
375:685-688[Medline].
|
| 30.
|
Manickan, E.,
R. J. D. Rouse,
Z. Yu,
W. S. Wire, and B. T. Rouse.
1995.
Genetic immunization against herpes simplex virus-protection is mediated by CD4+ T lymphocytes.
J. Immunol.
155:259-265[Abstract].
|
| 31.
|
Moore, M. W.,
F. R. Carbone, and M. J. Bevan.
1988.
Introduction of soluble protein into the class I pathway of antigen processing and presentation.
Cell
54:777-785[Medline].
|
| 32.
|
Nataraj, C.,
S. Eidmann,
M. J. Hariharan,
J. H. Sur,
G. A. Perry, and S. Srikumaran.
1997.
Bovine herpesvirus 1 downregulates the expression of bovine MHC class I molecules.
Viral Immunol.
10:21-34[Medline].
|
| 33.
|
Rahelu, M.,
G. T. Williams,
D. S. Kumraratne,
G. C. Eaton, and J. S. H. Gaston.
1993.
Human CD4+ cytolytic T cells kill antigen-pulsed target T cells by induction of apoptosis.
J. Immunol.
150:4856-4866[Abstract].
|
| 34.
|
Ramsdell, F.,
M. S. Seaman,
R. E. Miller,
K. S. Picha,
M. K. Kennedy, and D. H. Lynch.
1994.
Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death.
Int. Immunol.
6:1545-1553[Abstract/Free Full Text].
|
| 35.
|
Schmid, D. S.
1988.
The human MHC-restricted cellular response to herpes simplex virus type 1 is mediated by CD4+, CD8 T cells and is restricted to the DR region of the MHC complex.
J. Immunol.
1:3610-3616.
|
| 36.
|
Sigurdardottir, S.,
A. Lunden, and L. Andersson.
1988.
Restriction fragment length polymorphism of DQ and DR class II genes of the bovine major histocompatibility complex.
Anim. Genet.
19:133-150[Medline].
|
| 37.
|
Splitter, G. A.,
L. Eskra, and A. F. Abruzzini.
1988.
Cloned bovine cytolytic T cells recognize bovine herpes virus-1 in a genetically restricted, antigen-specific manner.
Immunology
63:145-150[Medline].
|
| 38.
|
Stalder, T.,
S. Hahn, and P. Erb.
1994.
Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity.
J. Immunol.
152:1127-1133[Abstract].
|
| 39.
|
Tikoo, S. K.,
M. Campos, and L. A. Babiuk.
1995.
Bovine herpesvirus 1 (BHV-1): biology, pathogenesis, and control.
Adv. Virus Res.
45:191-223[Medline].
|
| 40.
|
Torpey, D. J.,
M. D. Lindsley, and C. R. Rinaldo, Jr.
1989.
HLA-restricted lysis of herpes simple virus-infected monocytes and macrophages mediated by CD4+ and CD8+ T lymphocytes.
J. Immunol.
142:1325-1332[Abstract].
|
| 41.
|
Van den Broek, M. F.,
D. Kagi,
R. M. Zinkernagel, and H. Hengartner.
1995.
Perforin dependence of natural killer cell-mediated tumor control in vivo.
Eur. J. Immunol.
25:3514-3516[Medline].
|
| 42.
|
Viner, N. J.,
C. A. Nelson,
B. Deck, and E. R. Unanue.
1996.
Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing.
J. Immunol.
156:2365-2368[Abstract].
|
| 43.
|
Williams, N. S.,
V. H. Engelhard, and B. Beirne.
1996.
Identification of a population of CD4+ CTL that utilizes a perforin-rather than a Fas ligand-dependent cytotoxic mechanism.
J. Immunol.
156:153-159[Abstract].
|
| 44.
|
Yasukawa, M.,
A. Instsuki, and Y. Kobayashi.
1989.
Differential in vitro activation of CD4+CD8 and CD8+CD4 herpes simplex virus-specific human cytotoxic T cells.
J. Immunol.
143:2051-2057[Abstract].
|
| 45.
|
Yasukawa, M.,
Y. Yakushijin, and S. Fujita.
1996.
Two distinct mechanisms of cytotoxicity mediated by herpes simplex virus-specific CD4+ human cytotoxic T cell clones.
Clin. Immunol. Immunopathol.
78:70-76[Medline].
|
| 46.
|
Yasukawa, M., and J. M. Zarling.
1984a.
Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. I. Lysis restricted by HLA class II MB and DR antigens.
J. Immunol.
133:422-427[Abstract].
|
| 47.
|
Yasukawa, M., and J. M. Zarling.
1984b.
Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. II. Bifunctional clones with cytotoxic and virus-induced proliferative activities exhibit herpes simplex virus type 1 and 2 specific or type common reactivities.
J. Immunol.
133:2736-2742[Abstract].
|
| 48.
|
Yoo, J.,
R. T. Stone, and C. W. Beattie.
1996.
Cloning and characterization of the bovine Fas.
DNA Cell Biol.
15:227-234[Medline].
|
Journal of Virology, September 1998, p. 7040-7047, Vol. 72, No. 9
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bouhdoud, L., Villain, P., Merzouki, A., Arella, M., Couture, C.
(2000). T-Cell Receptor-Mediated Anergy of a Human Immunodeficiency Virus (HIV) gp120-Specific CD4+ Cytotoxic T-Cell Clone, Induced by a Natural HIV Type 1 Variant Peptide. J. Virol.
74: 2121-2130
[Abstract]
[Full Text]
-
Renjifo, X., Letellier, C., Keil, G. M., Ismaili, J., Vanderplasschen, A., Michel, P., Godfroid, J., Walravens, K., Charlier, G., Pastoret, P.-P., Urbain, J., Denis, M., Moser, M., Kerkhofs, P.
(1999). Susceptibility of Bovine Antigen-Presenting Cells to Infection by Bovine Herpesvirus 1 and In Vitro Presentation to T Cells: Two Independent Events. J. Virol.
73: 4840-4846
[Abstract]
[Full Text]